Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

Siliciano, Janet D, Kajdas, Joleen, Finzi, Diana, Quinn, Thomas C, Chadwick, Karen, Margolick, Joseph B, Kovacs, Colin, Gange, Stephen J +1 more·2003·Nature Medicine
DOI 10.1038/nm880

Cited by (1,001)

Items 301–400 of 1,001

  1. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents
    Amanda B. Macedo, Camille L. Novis, Caroline Maitan de Assis, Eric S. Sorensen, Paula Moszczynski, Szu-Han Huang, Yanqin Ren, Adam M. Spivak, Richard Brad Jones, Vicente Planelles et al. · 2018 · JCI Insight
  2. Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing
    Alice Cho, Christian Gaebler, Thiago Olveira, Víctor Ramos, Marwa Saad, Julio C. C. Lorenzi, Anna Gazumyan, Susan L. Moir, Marina F. Caskey, Tae‐Wook Chun et al. · 2022 · Proceedings of the National Academy of Sciences
  3. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
    Kersten K. Koelsch, Christoph Boesecke, Kristin L. McBride, Linda Gelgor, Paul Patrick Fahey, Ven Natarajan, David Baker, Mark Theo Bloch, John Michael Murray, John James Zaunders et al. · 2011 · AIDS
  4. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients
    Alejandro Vallejo, Carolina Gutiérrez, Beatriz Hernández‐Novoa, Laura Díaz, Nadia Madrid, María Abad-Fernández, Fernando Dronda, Marı́a Jesús Pérez-Elı́as, Javier Zamora, Eduardo Muñóz et al. · 2012 · AIDS
  5. HIV latency: experimental systems and molecular models
    Shweta Hakre, Leonard Chávez, Kotaro Shirakawa, Eric M. Verdin · 2012 · FEMS Microbiology Reviews
  6. No evidence of HIV replication in children on antiretroviral therapy
    Gert Uves van Zyl, Mary Grace Katusiime, Ann P. Wiegand, William R. McManus, Michael J. Bale, Elias Konstantine Halvas, Brian T. Luke, Valerie F. Boltz, Jonathan Spindler, Barbara Laughton et al. · 2017 · Journal of Clinical Investigation
  7. In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia
    Basiel Cole, Laurens Lambrechts, Pierre Gantner, Ytse Noppe, Noah Bonine, Wojciech Witkowski, Lennie Chen, Sarah Palmer, James I. Mullins, Nicolas Chomont et al. · 2021 · Nature Communications
  8. The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells
    Gabriel Duette, Bonnie Hiener, Hannah Morgan, Fernando G. Mazur, Vennila Mathivanan, Bethany A. Horsburgh, Katie Fisher, Orion Tong, Eunok Lee, Haelee Ahn et al. · 2022 · Journal of Clinical Investigation
  9. HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics
    Rutao Luo, Michael J. Piovoso, Javier Martínez‐Picado, Ryan Zurakowski · 2012 · PLoS ONE
  10. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes
    Gautam Kumar Sahu, Kyeongeun Lee, Jiaxiang Ji, Vivian Lam Braciale, Samuel Baron, Miles W. Cloyd · 2006 · Virology
  11. Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat
    Chuan Li, Guillaume Mousseau, Susana T. Valente · 2019 · Epigenetics & Chromatin
  12. Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAART
    Ahmad R. Sedaghat, Janet D'Angelo Siliciano, Timothy P. Brennan, Claus O. Wilke, Robert F. Siliciano · 2007 · PLoS Pathogens
  13. Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
    Mark E. Sharkey, Dunja Z. Babič, Thomas C. Greenough, Roy M. Gulick, Daniel R. Kuritzkes, Mario Stevenson · 2011 · PLoS Pathogens
  14. Measuring the latent reservoir in vivo
    Marta Massanella, Douglas D. Richman · 2016 · Journal of Clinical Investigation
  15. The forces driving clonal expansion of the HIV-1 latent reservoir
    Runxia Liu, Francesco Roberto Simonetti, Ya‐Chi Ho · 2020 · Virology Journal
  16. Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure
    Alyssa R. Martin, Robert F. Siliciano · 2015 · Annual Review of Medicine
  17. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells
    Fiona Wightman, Hao Kim Lu, Ajantha E. Solomon, Suha M. Saleh, Andrew Nicholas Harman, Anthony Lawrence Cunningham, Lachlan R. Gray, Melissa J. Churchill, Paul U. Cameron, Anthony E. Dear et al. · 2013 · AIDS
  18. The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4+T Cells
    Janet D'Angelo Siliciano, Robert F. Siliciano · 2015 · The Journal of Infectious Diseases
  19. Myeloid Cell Interaction with HIV: A Complex Relationship
    Vasco Rodrigues, Nicolas Ruffin, Mabel J. Jouve, Philippe Benaroch · 2017 · Frontiers in Immunology
  20. The role of integration and clonal expansion in HIV infection: live long and prosper
    Elizabeth M. Anderson, Frank M. Maldarelli · 2018 · Retrovirology
  21. Extracellular vesicles and chronic inflammation during HIV infection
    Paula S. Pérez, Marìa Albertina Romaniuk, Gabriel Duette, Zezhou Zhao, Yiyao Huang, Lorena Martin Jaular, Kenneth Whitaker Witwer, Clotilde Théry, Matías Ostrowski · 2019 · Journal of Extracellular Vesicles
  22. Targeting HIV Transcription: The Quest for a Functional Cure
    Guillaume Mousseau, Sonia Mediouni, Susana T. Valente · 2015 · Current topics in microbiology and immunology
  23. Hexamethylbisacetamide and Disruption of Human Immunodeficiency Virus Type 1 Latency in CD4+T Cells
    Shailesh Kumar Choudhary, Nancy M. Archin, David M. Margolis · 2008 · The Journal of Infectious Diseases
  24. Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection
    Natalia Soriano-Sarabia, Nancie M. Archin, Rosalie Bateson, Noelle Dahl, Amanda M. Crooks, JoAnn D. Kuruc, Carolina Garrido, David M. Margolis · 2015 · PLoS Pathogens
  25. The clinical applications of genome editing in HIV
    Cathy X. Wang, Paula M. Cannon · 2016 · Blood
  26. IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle
    Mayte Coiras, Mercedes Bermejo, Benjamin Descours, Elena Mateos, Javier García‐Pérez, María Rosa López‐Huertas, Michael M. Lederman, Monsef Benkirane, José Alcamı́ · 2016 · Cell Reports
  27. What Integration Sites Tell Us about HIV Persistence
    Stephen H. Hughes, John M. Coffin · 2016 · Cell Host & Microbe
  28. Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells
    Anwesha Sanyal, Robbie B. Mailliard, Charles R. Rinaldo, Deena M. Ratner, Ming Ding, Yue Chen, Jennifer M. Zerbato, Nicholas S. Giacobbi, Narasimhan J. Venkatachari, Bruce Kendrick Patterson et al. · 2017 · Nature Medicine
  29. Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence
    Amy S. Huang, Víctor Ramos, Thiago Y. Oliveira, Christian Gaebler, Mila Janković, Michel C. Nussenzweig, Lillian B. Cohn · 2021 · The Journal of Experimental Medicine
  30. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Philippe Halfon, Christoph Sarrazin · 2011 · Liver International
  31. Landscape review of current HIV ‘kick and kill’ cure research - some kicking, not enough killing
    Kristian Thorlund, Marc Steven Horwitz, Brian T. Fife, Richard Todd Lester, D. William Cameron · 2017 · BMC Infectious Diseases
  32. Insight into treatment of HIV infection from viral dynamics models
    Alison L. Hill, Daniel I. S. Rosenbloom, Martin A. Nowak, Robert F. Siliciano · 2018 · Immunological Reviews
  33. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood
    Freeling, Jennifer P., Koehn, Josefin, Shu, Cuiling, Sun, Jianguo, Ho, Rodney J.Y. · 2014 · AIDS
  34. Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy
    Shane D. Falcinelli, Kayla W. Kilpatrick, Jenna Read, Ross Murtagh, Brigitte Allard, Simon Ghofrani, Jennifer Kirchherr, Katherine Sholtis James, Erin L. Stuelke, Caroline Baker et al. · 2020 · The Journal of Infectious Diseases
  35. Reduction of HIV Persistence Following Transplantation in HIV-Infected Kidney Transplant Recipients
    Peter G. Stock, Burc Barin, Hiroyu Hatano, Rodney Rogers, Michelle E. Roland, T.-H. Lee, Michael Paul Busch, Steven G. Deeks · 2014 · American Journal of Transplantation
  36. Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy
    Aylin Yilmaz, Chris Verhofstede, Antonio D’Avolio, Victoria Watson, Lars Hagberg, Dietmar Fuchs, Bo Svennerholm, Magnus Gisslén · 2010 · JAIDS Journal of Acquired Immune Deficiency Syndromes
  37. No Evidence for Decay of the Latent Reservoir in HIV‐1–Infected Patients Receiving Intensive Enfuvirtide‐Containing Antiretroviral Therapy
    Rajesh Tim Gandhi, Ronald J. Bosch, Evgenia Aga, Mary Albrecht, Lisa M. Demeter, Carrie Dykes, Barbara Bastow, Michael F. Para, Jun Lai, Robert F. Siliciano et al. · 2009 · The Journal of Infectious Diseases
  38. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies
    Dominique Demonté, Vincent Quivy, Yves Colette, Carine M. Van Lint · 2004 · Biochemical Pharmacology
  39. Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study
    Marta Massanella, Rachel Bender Ignacio, Javier R. Lama, Amélie Pagliuzza, Sayan Dasgupta, Ricardo Alfaro, Jessica Ríos, Carmela Ganoza, Delia Pinto-Santini, Trupti Gilada et al. · 2021 · The Lancet Microbe
  40. The Histone Deacetylase Inhibitor Vorinostat (SAHA) Increases the Susceptibility of Uninfected CD4 + T Cells to HIV by Increasing the Kinetics and Efficiency of Postentry Viral Events
    Mark B. Lucera, Carisa A. Tilton, Hongxia Mao, Curtis N. Dobrowolski, Caroline O. Tabler, Aiman A. Haqqani, Jonathan Karn, John C. Tilton · 2014 · Journal of Virology
  41. Towards HIV-1 remission: potential roles for broadly neutralizing antibodies
    Ariel Halper-Stromberg, Michel C. Nussenzweig · 2016 · Journal of Clinical Investigation
  42. Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity
    Alyssa R. Martin, Ross A. Pollack, Adam A. Capoferri, Richard F. Ambinder, Christine M. Durand, Robert F. Siliciano · 2017 · Journal of Clinical Investigation
  43. Residual Viremia in Treated HIV+ Individuals
    Jessica M. Conway, Alan S. Perelson · 2016 · PLoS Computational Biology
  44. Recent developments in the effort to cure HIV infection: going beyond N = 1
    Janet D'Angelo Siliciano, Robert F. Siliciano · 2016 · Journal of Clinical Investigation
  45. Human Immunodeficiency Virus (HIV) Latency: The Major Hurdle in HIV Eradication
    Mudit Tyagi, Michael Bukrinsky · 2012 · Molecular Medicine
  46. Quinoline-based compounds as modulators of HIV transcription through NF-κB and Sp1 inhibition
    Luis Miguel Bedoya, Marı́a José Abad, Esther Calonge, Luís Astudillo Saavedra, Margarita Gutierrez C., Vladímir V. Kouznetsov, José Alcamı́, Paulina Bermejo · 2010 · Antiviral Research
  47. Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations
    Guinevere Q. Lee, Mathias D. Lichterfeld · 2016 · Current Opinion in HIV and AIDS
  48. Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir
    Zheng Wang, Francesco Roberto Simonetti, Robert F. Siliciano, Gregory M. Laird · 2018 · Retrovirology
  49. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy
    Slim Fourati, Philippe Flandre, Ruxandra Câlin, Guislaine Carcelain, Cathia Soulié, Sidonie Lambert-Niclot, Almoustapha Issiaka Maïga, Zaïna Ait-Arkoub, Roland Tubiana, Marc‐Antoine Valantin et al. · 2013 · Journal of Antimicrobial Chemotherapy
  50. Advances in Developing CAR T-Cell Therapy for HIV Cure
    Jinxin Qi, Chengchao Ding, Xian Li Jiang, Yong Gao · 2020 · Frontiers in Immunology
  51. A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads
    Kelly A. Metcalf Pate, Christopher W. Pohlmeyer, Victoria E. K. Walker-Sperling, Jeremy B. Foote, Kevin M. Najarro, Catherine G. Cryer, María Salgado, Lúcio Gama, Elizabeth L. Engle, Erin N. Shirk et al. · 2015 · The Journal of Infectious Diseases
  52. HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy
    Eva M. Stevenson, Adam R. Ward, Ronald Truong, Allison S. Thomas, Szu-Han Huang, Thomas R. Dilling, Sandra N. Terry, John K. Bui, Talia M. Mota, Ali Danesh et al. · 2021 · JCI Insight
  53. Modelling HIV immune response and validation with clinical data
    Harvey Thomas Banks, Marie Davidian, Shuhua Hu, Grace Martinelli Kepler, Eric S. Rosenberg · 2008 · Journal of Biological Dynamics
  54. Parthenium hysterophorus:A Probable Source of Anticancer, Antioxidant and Anti-HIV Agents
    Shashank Kumar, Gousia Chashoo, Ajit Kumar Saxena, Abhay Kumar Pandey · 2013 · BioMed Research International
  55. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection
    Perry Tsai, Guoxin Wu, Caroline Baker, William O. Thayer, Rae Ann Spagnuolo, Rosa I. Sánchez, Stephanie E. Barrett, Bonnie J. Howell, David M. Margolis, Daria J. Hazuda et al. · 2016 · Retrovirology
  56. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model
    Miguel A. Otero, Sandra A. Calarota, Barbara K. Felber, Dominick J. Laddy, George N. Pavlakis, Jean Boyer, David B. Weiner · 2004 · Vaccine
  57. HIV-1 eradication strategies
    Janet D'Angelo Siliciano, Robert F. Siliciano · 2013 · Current Opinion in HIV and AIDS
  58. Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control
    Christopher W. Pohlmeyer, Veronica D. Gonzalez, Alivelu Irrinki, Ricardo Ramírez, Li Li, Andrew S. Mulato, Jeffrey P. Murry, Aaron J. Arvey, Rebecca Hoh, Steven G. Deeks et al. · 2019 · Journal of Virology
  59. Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for HIV-Related Lymphoma
    Anthony Richard Cillo, Amrita Y. Krishnan, Ronald T. Mitsuyasu, Deborah K. McMahon, Shirley Li, John J. Rossi, John A. Zaia, John W. Mellors · 2013 · JAIDS Journal of Acquired Immune Deficiency Syndromes
  60. Anti-Apoptotic Genes in the Survival of Monocytic Cells During Infection
    Aurelia Busca, Mansi Saxena, Marko Kryworuchko, Ashok Kumar · 2009 · Current Genomics
  61. Entry of Polarized Effector Cells into Quiescence Forces HIV Latency
    Curtis N. Dobrowolski, Saba Valadkhan, Amy C. Graham, Meenakshi Shukla, Angela Ciuffi, Amalio Telenti, Jonathan Karn · 2019 · mBio
  62. Lost in Transcription: Molecular Mechanisms that Control HIV Latency
    Ran Taube, Boris Matija Peterlin · 2013 · Viruses
  63. Theoretical Design of a Gene Therapy To Prevent AIDS but Not Human Immunodeficiency Virus Type 1 Infection
    Leor S. Weinberger, David V. Schaffer, Adam P. Arkin · 2003 · Journal of Virology
  64. Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption
    Line K. Vibholm, Julio C. C. Lorenzi, Joy A. Pai, Yehuda Z. Cohen, Thiago Y. Oliveira, John P. Barton, Marco Garcia Noceda, Ching-Lan Lu, Yuria Ablanedo‐Terrazas, Perla M. Del Río Estrada et al. · 2019 · Journal of Virology
  65. The multifaceted nature of HIV latency
    Caroline Dufour, Pierre Gantner, Rémi Fromentin, Nicolas Chomont · 2021 · Journal of Clinical Investigation
  66. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity
    Steven A. Yukl, Satish K. Pillai, Peilin Li, Karen Chang, William Pasutti, Chris Ahlgren, Diane V. Havlir, Matthew C. Strain, Huldrych F. Günthard, Douglas D. Richman et al. · 2009 · Virology
  67. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model
    Jenna B. Honeycutt, Angela R. Wahl, Nancie M. Archin, Shailesh Kumar Choudhary, David M. Margolis, J. Víctor García · 2013 · Retrovirology
  68. New Frontiers in Measuring and Characterizing the HIV Reservoir
    Shane D. Falcinelli, Cristina Ceriani, David M. Margolis, Nancie M. Archin · 2019 · Frontiers in Microbiology
  69. Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy
    Marion Pardons, Rémi Fromentin, Amélie Pagliuzza, Jean‐Pierre Routy, Nicolas Chomont · 2019 · Cell Reports
  70. Drug-Resistant Variants That Evolve During Nonsuppressive Therapy Persist in HIV-1–Infected Peripheral Blood Mononuclear Cells After Long-Term Highly Active Antiretroviral Therapy
    Chris Verhofstede, Ann Noë, Els Demecheleer, Nancy De Cabooter, Filip Van Wanzeele, Bea Van Der Gucht, Dirk Vogelaers, Jean R. Plum · 2004 · JAIDS Journal of Acquired Immune Deficiency Syndromes
  71. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
    Sebastian P. Fuchs, Ronald C. Desrosiers · 2016 · Molecular Therapy — Methods & Clinical Development
  72. Gut microbiome signatures linked to HIV-1 reservoir size and viremia control
    Alessandra Borgognone, Marc Noguera-Julián, Bruna Oriol-Tordera, Laura Noël‐Romas, Marta Ruiz‐Riol, Yolanda Guillén, Mariona Parera, María Casadellà, Clara Duran-Castells, Maria Carmen Puertas et al. · 2022 · Microbiome
  73. Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique
    Amy E. Baxter, Julia Niessl, Rémi Fromentin, Jonathan Richard, Filippos Porichis, Marta Massanella, Nathalie Brassard, Nirmin Alsahafi, Jean‐Pierre Routy, Andrés Finzi et al. · 2017 · Nature Protocols
  74. Compartmentalized Human Immunodeficiency Virus Type 1 Present in Cerebrospinal Fluid Is Produced by Short-Lived Cells
    Patrick R. Harrington, David W. Haas, Kimberly Ritola, Ronald I. Swanstrom · 2005 · Journal of Virology
  75. Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents
    David M. Margolis, Nancie M. Archin · 2016 · The Journal of Infectious Diseases
  76. Dendritic cell based vaccines for HIV infection
    Felipe García, Montserrat Plana, Núria Climent, Agathe León, José M. Gatell, Teresa Gallart · 2013 · Human Vaccines & Immunotherapeutics
  77. Slow Human Immunodeficiency Virus Type 1 Evolution in Viral Reservoirs in Infants Treated with Effective Antiretroviral Therapy
    Deborah Persaud, Stuart C. Ray, Joleen Kajdas, Aima A. Ahonkhai, George Kelly Siberry, Kimberly C. Ferguson, Carrie Ziemniak, Thomas C. Quinn, Joseph P. Casazza, Steven L. Zeichner et al. · 2007 · AIDS Research and Human Retroviruses
  78. Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the Brain
    Lachlan R. Gray, Michael Roche, Melissa J. Churchill, Jasminka Sterjovski, Anne M. Ellett, Pantelis Poumbourios, Shameem Sheffief, Bin Wang, Nitin K. Saksena, Damian F. J. Purcell et al. · 2009 · Journal of Virology
  79. Role of histone modification on transcriptional regulation and HIV-1 gene expression: possible mechanisms of periodontal diseases in AIDS progression
    Kenichi Imai, Kuniyasu Ochiai · 2011 · Journal of Oral Science
  80. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
    Erik Sörstedt, Staffan Nilsson, Anders Blaxhult, Magnus Gisslén, Leo Flamholc, Anders B. Sönnerborg, Aylin Yilmaz · 2016 · BMC Infectious Diseases
  81. Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs
    Justin R. Bailey, Joel N. Blankson, Megan Wind‐Rotolo, Robert F. Siliciano · 2004 · Current Opinion in Immunology
  82. Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist
    Katsunori Takashima, Hiroshi Miyake, Naoyuki Kanzaki, Yoshihiko Tagawa, Xin Wang, Yoshihiro Sugihara, Yuji Iizawa, Masanori Baba · 2005 · Antimicrobial Agents and Chemotherapy
  83. Identification, Quantification, and Characterization of HIV-1 Reservoirs in the Human Brain
    Maribel Donoso, Daniela C.S. Damico, Silvana Valdebenito, Cristian A. Hernandez, Brendan Prideaux, Eliseo A. Eugenín · 2022 · Cells
  84. Comparison of digital PCR platforms and semi-nested qPCR as a tool to determine the size of the HIV reservoir
    Kobus J. Bosman, Monique Nijhuis, Petra M. van Ham, Annemarie M. J. Wensing, Karen Vervisch, Linos Vandekerckhove, Ward De Spiegelaere · 2015 · Scientific Reports
  85. Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248
    Adriana S. Andrade, Susan L. Rosenkranz, Anthony Richard Cillo, Darlene Lu, Eric S. Daar, Jeffrey M. Jacobson, Michael M. Lederman, Edward P. Acosta, Thomas Campbell, Judith Feinberg et al. · 2013 · The Journal of Infectious Diseases
  86. TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia
    Gregory Q. Del Prete, W. Gregory Alvord, Yuan Li, Claire Deléage, Mukta Nag, Kelli A. Oswald, James Andrew Thomas, Cathi Pyle, William J. Bosche, Vicky J. Coalter et al. · 2019 · JCI Insight
  87. Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies
    Tram M. Ta, Sajjaf Malik, Elizabeth M. Anderson, Amber D. Jones, Jocelyn Perchik, Maryann Freylikh, Luca Sardo, Zackary A. Klase, Taisuke Izumi · 2022 · Frontiers in Microbiology
  88. Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy
    Sara Gianella, Sergei L. Kosakovsky Pond, Michelli F. Oliveira, Konrad Scheffler, Matthew C. Strain, Antonio De la Torre, Scott Lee Letendre, Davey Mitchell Smith, Ronald J. Ellis · 2016 · Virus Evolution
  89. Gag-Positive Reservoir Cells Are Susceptible to HIV-Specific Cytotoxic T Lymphocyte Mediated Clearance In Vitro and Can Be Detected In Vivo
    Erin H. Graf, Matthew J. Pace, Bennett A. Peterson, Lindsay J. Lynch, Steve B. Chukwulebe, Angela M. Mexas, Farida Shaheen, Jeffrey N. Martin, Steven G. Deeks, Mark Connors et al. · 2013 · PLoS ONE
  90. A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence
    Michelle Kim, Nina N. Hosmane, C. Korin Bullen, Adam A. Capoferri, Hung‐Chih Yang, Janet D'Angelo Siliciano, Robert F. Siliciano · 2014 · Nature Protocols
  91. Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells
    Wen Shi Lee, Jonathan Richard, Marit Lichtfuss, Amos B. Smith, Jongwoo Park, Joel R. Courter, Bruno N. Melillo, Joseph Sodroski, DE Kaufmann, Andrés Finzi et al. · 2015 · Journal of Virology
  92. Blood CXCR3+ CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals
    Riddhima Banga, Francesco A. Procopio, Alessandra Ruggiero, Alessandra Noto, Khalid Ohmiti, Matthias L. Cavassini, Jean-Marc Corpataux, William A. Paxton, Georgios Pollakis, Matthieu Perreau · 2018 · Frontiers in Immunology
  93. Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal
    Christine Marian, Mateusz Stoszko, Lili Wang, Matthew W. Leighty, Elisa De Crignis, Chad A. Maschinot, Jovylyn Gatchalian, Benjamin C. Carter, Basudev Chowdhury, Diana C. Hargreaves et al. · 2018 · Cell chemical biology
  94. The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like
    Gilles Darcis, Ben Berkhout, Alexander O. Pasternak · 2019 · Frontiers in Immunology
  95. The Glutamate System as a Crucial Regulator of CNS Toxicity and Survival of HIV Reservoirs
    Anna Maria Górska, Eliseo A. Eugenín · 2020 · Frontiers in Cellular and Infection Microbiology
  96. Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy
    John M. Coffin, Michael J. Bale, Daria Wells, Shuang Guo, Brian T. Luke, Jennifer M. Zerbato, Michele D. Sobolewski, Twan W. Sia, Wei Shao, Xiaolin Wu et al. · 2021 · PLoS Pathogens
  97. Polyamides Reveal a Role for Repression in Latency within Resting T Cells of HIV‐Infected Donors
    Loyda Ylisastigui, Jason J. Coull, Victor C. Rucker, Christian Melander, Ronald J. Bosch, Scott J. Brodie, Lawrence Corey, Donald L. Sodora, Peter B. Dervan, David M. Margolis · 2004 · The Journal of Infectious Diseases
  98. Enfermedades Infecciosas y Microbiología Clínica
    Rafael Bastos Delgado · 2016
  99. Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversity
    Gérémy Sannier, Mathieu Dubé, Caroline Dufour, Corentin Richard, Nathalie Brassard, Gloria-Gabrielle Ortega-Delgado, Amélie Pagliuzza, Amy E. Baxter, Julia Niessl, Elsa Brunet‐Ratnasingham et al. · 2021 · Cell Reports
  100. Sex Differences in Human Immunodeficiency Virus Persistence and Reservoir Size During Aging
    Sara Gianella, Stephen A. Rawlings, Curtis N. Dobrowolski, Masato Nakazawa, Antoine Chaillon, Matthew C. Strain, Laura Layman, Gemma Caballero, Eileen P. Scully, Brianna Scott et al. · 2021 · Clinical Infectious Diseases